Batavia Biosciences joins international consortium developing polio vaccines

16 January 2018
2019_biotech_test_vial_discovery_big

A project to develop safer, novel oral poliovirus vaccines has recruited a new partner, the privately-held Dutch firm Batavia Biosciences.

Funded by the Bill & Melinda Gates Foundation, the project is coordinated by PATH, a non-profit focused on developing health innovations to tackle public health issues.

Novel oral polio vaccine candidates are being developed with the aim of reducing the risk from rare cases of vaccine-associated disease. The novel strains will be stockpiled as protection against possible future outbreaks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology